Skip to content

US · XNCR · BIOTECHNOLOGY

Xencor, Inc. (XNCR) intrinsic value and stock valuation

$33.26as of 2026-11-21 · Mkt cap 1.47B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Xencor, Inc. DCF and intrinsic value

InvestorsCraft values XNCR with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from XNCR’s statements →

Xencor, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Pasadena, CA 91107 xencor.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$125.6M+0.5% 5y CAGRd
20112025
Net income
-$-91.92M
20112025
Free cash flow
-$-138.27M
20112025
Total equity
$635.6M+2.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$125.6M$110.5M$174.6M$164.6M$275.1M
Operating income-$-177.5M-$-178.41M-$-132.36M-$-82.47M$43.8M
Net income-$-91.92M-$-232.62M-$-133.13M-$-55.18M$82.6M
EPSd-$-1.24M-$-3.58M-$-2.2M-$-925.06K$1.37M
Operating cash flow-$-135.12M-$-202.19M-$-77.93M$24.5M-$-16.85M
Capital expenditure-$-3.15M-$-6.1M-$-18.45M-$-43.4M-$-15.98M
Free cash flow-$-138.27M-$-208.28M-$-96.37M-$-18.92M-$-32.83M
Total assets$875.5M$952M$952.7M$846.3M$838.2M
Total debt$187.8M$232M$83.4M$59.6M$34M
Net debt$133.7M$191.1M$29.6M$5.69M-$-109.51M
Total equity$635.6M$674M$669.1M$727.5M$733.5M
Cash and short-term investments$547.7M$497.8M$593.7M$623.1M$334.1M
Income statement
20252024202320222021
Revenue$125.6M$110.5M$174.6M$164.6M$275.1M
Cost of revenue$10.5M$227.7M$0.00$199.6M$192.5M
Gross profit$115.1M-$-117.19M$174.6M-$-34.98M$82.6M
Research and development expenses$239.4M$227.7M$253.6M$199.6M$192.5M
Selling, general and administrative expenses$63.6M$58.9M$53.4M$47.5M$38.8M
Other expenses-$-10.51M-$-225.36M$0.00-$-199.56M-$-192.51M
Operating expenses$292.6M$61.2M$307M$47.5M$38.8M
Cost and expenses$303.1M$288.9M$307M$247.1M$231.3M
Interest income$27.5M$31.9M$18.6M$4.82M$860K
Interest expense$31.9M$36.6M$0.00$0.00$10K
Depreciation and amortization$10.5M$12.1M$11.5M$8.8M$7.49M
Ebitda-$-46.98M-$-186.17M-$-101.96M-$-45.7M$90.1M
Operating income-$-177.5M-$-178.41M-$-132.36M-$-82.47M$43.8M
Total other income/expenses, net$87.9M-$-56.52M$12.7M$28M$38.9M
Income before tax-$-89.42M-$-234.92M-$-119.63M-$-54.51M$82.6M
Income tax expense$2.5M$1.62M$13.7M$670K$0.00
Net income-$-91.92M-$-232.62M-$-133.13M-$-55.18M$82.6M
Weighted average shares outstanding$74.2M$65M$60.5M$59.7M$58.4M
Weighted average diluted shares outstanding$74.2M$65M$60.5M$59.7M$60.5M
Balance sheet
20252024202320222021
Cash and short-term investments$547.7M$497.8M$593.7M$623.1M$334.1M
Net receivables$29.3M$60.9M$11.3M$29M$66.4M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$599.8M$577.6M$623.2M$675.3M$424.4M
Property, plant and equipment, net$90.9M$98.1M$100.1M$93.6M$60M
Goodwill and intangible assets$8.38M$18.5M$18.7M$18.5M$16.5M
Long-term investments$175.9M$256.8M$209.7M$58.2M$331.7M
Total non-current assets$275.7M$374.3M$329.5M$170.9M$413.8M
Total assets$875.5M$952M$952.7M$846.3M$838.2M
Accounts payable$10.8M$16.8M$13.9M$10.1M$14M
Short-term debt$46.5M$51.5M$9.77M$4.71M$0.00
Deferred revenue$0.00$0.00$31.7M$30.3M$37.3M
Total current liabilities$95.9M$87.4M$84.7M$63.8M$70.7M
Long-term debt$141.2M$180.5M$73.7M$54.9M$34M
Deferred revenue, non-current$0.00$0.00$125.2M$0.00$0.00
Total non-current liabilities$144M$190.5M$198.9M$54.9M$34M
Capital lease obligations$68M$68.4M$62.5M$59.6M$34M
Total liabilities$239.9M$277.9M$283.6M$118.8M$104.7M
Common stock$720K$700K$610K$600K$590K
Retained earnings-$-795.96M-$-704.04M-$-464.37M-$-338.29M-$-283.1M
Accumulated other comprehensive income (loss)$1.58M-$-660K$1.29M-$-6.95M-$-1.51M
Total equity$635.6M$674M$669.1M$727.5M$733.5M
Total investments$669.6M$713.7M$749.7M$627.3M$522.4M
Total debt$187.8M$232M$83.4M$59.6M$34M
Net debt$133.7M$191.1M$29.6M$5.69M-$-109.51M
Cash flow statement
20252024202320222021
Net income-$-91.92M-$-236.54M-$-133.13M-$-55.18M$82.6M
Depreciation and amortization$10.5M$12.1M$11.5M$8.8M$7.49M
Stock-based compensation$43.2M$53.3M$0.00$48.9M$37M
Change in working capital$47.5M-$-40.4M$19.1M$48.9M-$-102.6M
Accounts receivable$28.7M-$-32.67M$19.8M$36.9M-$-54.94M
Inventory$0.00$0.00$0.00$0.00$1.4M
Accounts payable-$-3.95M$2.85M$3.83M-$-3.91M$5.05M
Net cash provided by operating activities-$-135.12M-$-202.19M-$-77.93M$24.5M-$-16.85M
Investments in property, plant and equipment-$-3.15M-$-6.1M-$-21.25M-$-38.49M-$-15.98M
Acquisitions, net$0.00$0.00$500K$0.00-$-2.66M
Net cash used for investing activities$140M-$-7.87M-$-110.56M-$-119.72M-$-46.25M
Common stock issued$9.96M$201.3M$5.39M$0.00$28.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.23M$197.2M$188.7M$5.7M$43M
Net change in cash$13.1M-$-12.91M-$-150K-$-89.54M-$-20.06M
Cash at end of period$54.4M$41.3M$53.8M$53.9M$143.5M
Operating cash flow-$-135.12M-$-202.19M-$-77.93M$24.5M-$-16.85M
Capital expenditure-$-3.15M-$-6.1M-$-18.45M-$-43.4M-$-15.98M
Free cash flow-$-138.27M-$-208.28M-$-96.37M-$-18.92M-$-32.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Xencor, Inc.

        Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.

        CEO
        Bassil I. Dahiyat
        Employees
        260
        Beta
        0.86

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Xencor, Inc. (XNCR)?

        Xencor, Inc. (XNCR) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is XNCR undervalued?

        XNCR trades at a price of $33.26 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.